Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer with and without DNA Repair Defects

Scientists conducted a Phase II, multi-center, single-arm trial evaluating nivolumab in post-docetaxel metastatic castration-resistant prostate cancer patients. DNA repair defects was assessed using circulating tumor DNA.